comparemela.com

Latest Breaking News On - Radiopharmaceuticals - Page 1 : comparemela.com

Radioactive taste: Mariana glows for Novartis in $1 75B deal

Novartis AG is bolstering its radioligand arsenal with the takeout of Mariana Oncology Inc. for $1 billion up front and as much as $750 million in potential milestone payments. Watertown, Mass.-based Mariana has developed peptide-based radiopharmaceuticals targeting solid tumors. The company’s lead program, MC-339, is a radioligand approach to small-cell lung cancer, due to enter the clinic later this year.

Mariana oncology incMariana oncologyNovartis agMariana oncology incSolid tumorsMc 339Small cell lung cancerRadioligand therapyDeals andm amp a

Novartis, Peptidream expand peptide discovery effort in $2 7B deal

Novartis Pharma AG continues to build up its radiopharmaceutical powerhouse and has expanded a peptide discovery collaboration with Peptidream Inc. in a deal worth up to $2.71 billion. Under the multi-program agreement, Kawasaki, Japan-based Peptidream will use its peptide discovery platform system technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis for potential conjugation to radioligand therapies or other applications for both therapeutic and diagnostic purposes.

Peptidream incNovartis pharmaJapan based peptidreamNovartis agPeptidream incAsia pacificDeals andm amp a

Gamma Camera | Scintillation Camera

Gamma cameras may not be as well-known as x-rays or CT scans, but they are invaluable to radiology and various medical specialties like oncology. Find out how they work & why we need them.

Nuclear scanSafety ensuredGamma cameraCintillation cameraNuclear medicine

What s old is new again in the fight against cancer

What s old is new again in the fight against cancer
beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.

Street journalMeta keywords drugmakersTargeted therapyAntibody drug conjugates

ITM Appoints Dr Mark Harfensteller as Member of its

Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the.

Gerrit siegersA societas europaeaSebastian marxSteffen schusterBen orzelekMark harfenstellerKlaus maleckCanadian nuclear laboratoriesTechnical university of munichCorporate communicationsGroup as head of engineeringInstitute of machine toolsChief operating officerManaging directorIsotopes gmbhGood manufacturing practice

vimarsana © 2020. All Rights Reserved.